Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
smn;9.0 to 153.2±8.9 mmHg; baseline vs. end oftreatment). Diastolic blood pressure was also significantly reducedby 9.8 mmHg from 91.3±7.8 to 81.5±8.2 mmHg(p0.001) in the SPP635 treated group compared to the placebotreatment (95.3±5.1 to 93.3±5.4 mmHg). These bloodpressure measurements were taken at trough 24 hours after theprevious medication. Similar re
smn;9.0 to 153.2±8.9 mmHg; baseline vs. end of
treatment). Diastolic blood pressure was also significantly reduced
by 9.8 mmHg from 91.3±7.8 to 81.5±8.2 mmHg
(p<0.001) in the SPP635 treated group compared to the placebo
treatment (95.3±5.1 to 93.3±5.4 mmHg). These blood
pressure measurements were taken at trough, 24 hours after the
previous medication. Similar results were observed for ambulatory
blood pressures, which were reduced both during the day as well as
in the night.
The half-life of SPP635 had been previously reported to be
approximately 24 hours suggesting once daily administration; these
latest ambulatory blood pressure data confirm the use as of SPP635
as an once-a-day drug. The extent of blood pressure reduction is
similar to those reported for the renin inhibitor SPP100
Hans R. Brunner, Professor Emeritus of Medicine at the University
of Lausanne, and acting Speedel Medical Director, commented: "These
positive results show that SPP635 has comparable efficacy to other
blood pressure lowering therapies. It will be exciting to see the
first follow-on renin inhibitor to SPP100 demonstrate its potential
in diabetic patients in further clinical trials."
Alice Huxley, CEO of Speedel, commented: "This success with SPP635
reinforces Speedel's strategy of building a family of renin
inhibitors which can be profiled for both general and special
patient populations. We continue to leverage our exceptional
knowledge in renin inhibition which we believe has the potential to
be the next gold standard for the treatment of different
Continued Phase II development
Clinical profiling of SPP635 will continue this year in special
populations with a further study planned in diabetic patients with
mild-to-moderate hypertension. This harder to manage patient group
has been shown to respond to SPP100 to controlling blood pr '"/>
(Date:4/28/2015)... 2015 Rosa & Co. LLC, a drug development ... today announced its pleasure to be lead partner for ... Systems Pharmacology (QSP). The conference focuses on uses and ... Logo - ... Rosa,s lead sponsorship is the second of ...
(Date:4/28/2015)... -- Boston Scientific Corporation (NYSE: BSX ) generated ... ended March 31, 2015, compared to the company,s ... $1.800 billion. This represents 6 percent operational revenue ... flat revenue on a reported basis, all compared ... adjusted earnings per share of $0.21 for the ...
(Date:4/28/2015)... INDIANAPOLIS , April 28, 2015 People with ... receive a heart stent are prescribed an oral antiplatelet (OAP) ... blood clot in their heart stent (stent thrombosis), or even ... that 52 percent of 275 ACS patients who were currently ... they take their prescribed OAP therapy, even though most of ...
(Date:4/28/2015)... April 28, 2015 2015 Market ... is a professional and in-depth research report. The ... application, industry overview, industry chain structure, international market ... covers the global (US, Europe, Japan, Asia) and ... macroeconomic environment & economic situation analysis. The Global ...
(Date:4/28/2015)... biologics safety testing market is growing at a favorable ... of the pharmaceutical and biological industries and an increasing ... number of drug approvals in North American countries has ... drug applications and Health Canada approved 99. In addition, ... pharmaceutical and 1,998 of the biotechnology patents granted in ...
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 28, 2015 A first-in-human prostate ... Molecular Imaging and Biology showed initial safety, biodistribution, ... fluorine-18 labeled small-molecule PSMA inhibitor. The imaging biomarker ... Baltimore, MD by study co-author, Martin G. Pomper, ... of [18F]DCFPyL demonstrated a number of important findings. ...
(Date:4/28/2015)... 2015 The buyer power score for ... 5, indicating a medium level of buyer power in ... have equal power during negotiations. One factor helping buyer ... a health insurance policy from an insurance carrier (such ... can choose to self-fund their own policy or forgo ...
... strain is similar to that seen in 1918, with ... 24 (HealthDay News) -- The 2009 H1N1 "swine flu" ... early in the 20th century, two teams of scientists ... people seemed to be less affected by H1N1 during ...
... Tuesday, President Obama signed into law U.S. health care ... affect them, their families, and businesses. The ... 2006 legislation in Massachusetts requiring all adults in the ... mandate. A new article from The Milbank Quarterly ...
... , ... Another Group Logic Solution to Their Product Portfolio , ... (PRWEB) March 24, 2010 -- Group Logic, the ... the United Kingdom, Jigsaw Systems, is adding the MassTransit product line to its solution ...
... ... solution will power health information exchange across LSU hospital system for more than 2800 ... ... will be able to access patient information across the 10 rural and metropolitan hospitals ...
... This release is available in Spanish . ... area as the original tumour remains the strongest, independent prognostic ... have been free of disease for a very long time, ... Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, a ...
... - Despite the aches and pains that occur in old ... positive experiences from their past. A new study, reported ... ( http://www.elsevier.com/locate/cortex ), reveals that older adults, ability to remember ... way in which the brain processes emotional content. In ...